# Study of JAB-23E73 in Combination With Chemotherapy in Participants With Metastatic PDAC Harboring KRAS Gene Alterations

> **NCT07640295** · PHASE1,PHASE2 · RECRUITING · sponsor: **Jacobio Pharmaceuticals Co., Ltd.** · enrollment: 80 (estimated)

## Conditions studied

- Metastatic Pancreatic Ductal Adenocarcinoma

## Interventions

- **DRUG:** JAB-23E73 tablet，nab-paclitaxel，gemcitabine

## Key facts

- **NCT ID:** NCT07640295
- **Lead sponsor:** Jacobio Pharmaceuticals Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-07-16
- **Primary completion:** 2029-12-31
- **Final completion:** 2030-12-31
- **Target enrollment:** 80 (ESTIMATED)
- **Last updated:** 2026-08-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07640295

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07640295, "Study of JAB-23E73 in Combination With Chemotherapy in Participants With Metastatic PDAC Harboring KRAS Gene Alterations". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07640295. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*